BioNet-Asia Co. Ltd.

What BioNet-Asia Co. Ltd. does

BioNet-Asia Co., Ltd. is a Franco-Thai vaccine biotechnology company founded around 2000 and headquartered in Bangkok, Thailand, with a regional headquarters in Lyon, France and vaccine manufacturing operations in Ayutthaya, Thailand. The company specializes in the development and biomanufacturing of recombinant and mRNA vaccines targeting respiratory diseases and other global public health threats, with its commercial portfolio anchored by recombinant acellular pertussis (whooping cough) vaccines. BioNet currently markets 3 licensed recombinant pertussis vaccines, including the world's only monovalent acellular pertussis vaccine (VacPertagen, marketed as Pertagen in Asia) and a combined TdaP vaccine (Tdapgen). Its core proprietary technology is PTgen, a genetically detoxified pertussis toxin that preserves native antigen conformation and has demonstrated 5+ years of antibody persistence in clinical data, materially exceeding chemically inactivated incumbents. The company also maintains a pipeline of 10+ mRNA vaccine candidates.

BioNet generates revenue through direct sales of its licensed vaccine products to national immunization programs, public health authorities, and healthcare providers across 25 countries, with direct commercial presence in Europe and Asia-Pacific. Its go-to-market is sales-led, leveraging long-standing government and public health relationships as well as strategic distribution and co-development partnerships — notably with Indonesia's state-owned PT Bio Farma for ASEAN TdaP access and with Germany's LTS Lohmann Therapie-Systeme AG for microneedle mRNA delivery (BARDA Patch Forward Prize, January 2025). In October 2025 BioNet's Lyon facility received EU-GMP certification from the HPRA of Ireland, in November 2025 VacPertagen received a positive CHMP opinion from the EMA, and in January 2026 the European Commission granted marketing authorization — making it the first standalone pertussis-only vaccine approved in the EU for teenagers, adults, and pregnant women. The company is privately held with roughly 200+ employees and reports no disclosed external venture or private equity backing.

Name

BioNet-Asia Co. Ltd.

Legal name

BioNet-Asia Co., Ltd.

Website

https://bionet-asia.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

251–500 employees

Short description

Franco-Thai vaccine biotech developing recombinant and mRNA vaccines, anchored by the world's only monovalent acellular pertussis vaccine (VacPertagen). It sells directly to governments and public health systems across 25 countries.

Ownership category

akta.pro rank

Product category

Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Maternal Vaccines (Pregnancy) (HLAIAEAC)

Keywords

• Recombinant vaccines
• MRNA vaccines
• Pertussis vaccines
• Vaccine manufacturing
• Biotechnology pharmaceuticals

Headquarters

HQ city

Bangkok

HQ country

Thailand

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Vaccine Product Sales: BioNet markets multiple licensed recombinant pertussis vaccines through its established commercial network across 25 countries

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioNet develops, manufactures, and commercializes recombinant and mRNA vaccines against respiratory diseases and global public health threats, with a primary focus on pertussis (whooping cough). The company markets three licensed recombinant pertussis vaccines—including monovalent acellular formulations (VacPertagen/Pertagen) and combined TdaP vaccines (Tdapgen)—using its proprietary genetically detoxified pertussis toxin (PTgen) technology, and is developing 10+ mRNA vaccine candidates for respiratory diseases and other public health threats.

Product overview

BioNet-Asia Co. Ltd. is a vaccine manufacturer specializing in recombinant and mRNA vaccines against respiratory diseases and global public health threats. The company operates a multi-product portfolio anchored by its recombinant pertussis vaccine platform (VacPertagen/Pertagen®, aPgen, Tdapgen) and expanding into mRNA vaccine development. BioNet holds 3 licensed recombinant pertussis vaccines and maintains 10+ mRNA candidates in its pipeline. The products include monovalent pertussis-only vaccines (VacPertagen/Pertagen®) and combination TdaP vaccines, all utilizing the company's proprietary genetically detoxified pertussis toxin (PTgen) technology. Manufacturing complies with EU-GMP and PIC/S standards.

Differentiator

Problem solved

Functional benefit

Brands

• VacPertagen: World's only available monovalent acellular pertussis vaccine containing two components including a recombinant Pertussis Toxin (PTgen). Marketed as Pertagen in Asia.
• Pertagen

Products and services

• VacPertagen World's only monovalent acellular pertussis vaccine containing recombinant Pertussis Toxin (PTgen). Approved by the European Commission for booster immunization in individuals 12 years and above and passive immunization during pregnancy.
• aPgen Pertussis-only formulation containing 5 µg PTgen and 5 µg FHA. Licensed for immunization of individuals aged 11 years and older. Also available in reduced-dose version (2 µg PTgen).
• Tdapgen Combined tetanus-diphtheria-pertussis formulation with recombinant pertussis toxin. Licensed in Thailand since 2016 for immunization of individuals aged 3 years and older. Also available in reduced-dose formulation.
• TdaP Vaccine (ASEAN) Combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis) developed with Bio Farma for ASEAN distribution. Available in full-dose and reduced-dose formulations.
• mRNA Vaccine Candidates Pipeline of 10+ mRNA vaccine candidates targeting respiratory diseases and other global public health threats, including an mRNA COVID-19 vaccine produced at BioNet's factory in Ayutthaya, Thailand.

Quantifiable outcome

• Anti-PT antibodies remained elevated 5 years after booster vaccination with recombinant pertussis vaccine containing PTgen
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core, major and supporting.

• PT Bio Farma (Persero)coreStrategic or Co-development Partner · 28 May 2025BioNet signed a Memorandum of Understanding with Indonesia's state-owned vaccine manufacturer Bio Farma to collaborate on development and regional distribution of combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis) in ASEAN countries.
• LTS Lohmann Therapie-Systeme AGcoreStrategic or Co-development Partner · 17 January 2025LTS and BioNet won the U.S. BARDA Patch Forward Prize competition for microneedle mRNA vaccine innovation. LTS is a leading pharmaceutical technology company and BioNet is a biotech manufacturer specializing in genetically engineered vaccines.
• TechnovaliamajorStrategic or Co-development Partner · 1 January 2021Collaboration on Covigen DNA-based COVID-19 vaccine candidate development with PharmaJet needle-free delivery technology
• PharmaJetsupportingTechnology or Integration · 1 January 2021PharmaJet provides needle-free injection systems (Tropis and Stratis) for delivery of BioNet's COVID-19 vaccine candidates in clinical trials
• Faculty of Medicine, Chulalongkorn UniversitymajorStrategic or Co-development PartnerClinical collaboration on next-generation pertussis vaccine research and development in Thailand

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sanofi Pasteur: The vaccines division of Sanofi is a global leader in pertussis combination vaccines (Tdap/TdaP, e.g., Repevax, Adacel) and competes directly with BioNet's VacPertagen in booster and maternal immunization markets, but operates at vastly larger scale across a full vaccine portfolio.
• GSK: GSK's vaccines business (Boostrix, Infanrix) competes with BioNet in the pertussis combination and adolescent/adult booster market, with deep relationships in EU national immunization programs that BioNet must now navigate as a new entrant.
• Merck & Co. Merck is a major pertussis-containing combination vaccine player (Vaxelis, Adacel licensee in some markets) and a broad vaccine incumbent that competes with BioNet for public-health tenders and shares the regulated vaccine market dynamics.
• Serum Institute of India: The world's largest vaccine manufacturer by volume, producing aP-containing combination vaccines at significant scale. Competes with BioNet on price-sensitive emerging-market tenders and shares a focus on affordable, high-volume vaccine supply.

Regional players

• PT Bio Farma: Indonesia's state-owned vaccine manufacturer and BioNet's strategic MoU partner for TdaP distribution in ASEAN. Bio Farma is both a peer (vaccine manufacturer serving regional public-health systems) and a distribution partner, with strong regional market access in Southeast Asia.

Emerging players

• Bharat Biotech: India-based vaccine manufacturer with a broad portfolio (including rotavirus, COVID-19, and combination vaccines) that competes with BioNet in emerging markets and shares a similar scale and growth-stage profile as a private-to-emerging vaccine innovator.
• CureVac: mRNA-focused vaccine company developing infectious disease and oncology vaccines. Comparable to BioNet's mRNA platform ambitions and target market, but with deeper mRNA-specific expertise and public-market capital access.
• Novavax: Protein-based recombinant vaccine company with COVID-19 and respiratory pipeline experience. Shares BioNet's recombinant vaccine technology orientation and emerging-market commercialization challenges, particularly in Asia-Pacific.
• Bavarian Nordic: Vaccine company with a focus on infectious disease and public-health preparedness, including mRNA-based programs. Comparable to BioNet in scale and public-health customer orientation, with similar exposure to government procurement dynamics.

Direct peers

• Moderna: Direct peer in the mRNA vaccine platform category where BioNet has 10+ candidates. Moderna is the established mRNA leader and represents both the most significant competitor and the highest benchmark for BioNet's mRNA platform ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioNet-Asia Co. Ltd.